Subsequently, in a phase III study, which compared nivolumab with dacarbazine in patients with melanoma without B-Raf mutation, nivolumab was associated with a survival benefit (73 versus 42%) and higher objective response rate (40 versus 14%). The gene discussed is BRAF; the disease is melanoma.